LBA1_PRIMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). (23rd October 2018) - Schmid, P; Adams, S; Rugo, H S; Schneeweiss, A; Barrios, C H; Iwata, H; Dieras, V; Hegg, R; Im, S-A; Wright, G S; Henschel, V; Molinero, L; et al.